- Home
- M vs KYMR Comparison
M vs KYMR Comparison
Compare M & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- M
- KYMR
- Stock Information
- Founded
- M 1830
- KYMR 2015
- Country
- M United States
- KYMR United States
- Employees
- M N/A
- KYMR N/A
- Industry
- M Department/Specialty Retail Stores
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- M Consumer Discretionary
- KYMR Health Care
- Exchange
- M Nasdaq
- KYMR Nasdaq
- Market Cap
- M 4.9B
- KYMR 4.2B
- IPO Year
- M N/A
- KYMR 2020
- Fundamental
- Price
- M N/A
- KYMR $56.66
- Analyst Decision
- M Hold
- KYMR Strong Buy
- Analyst Count
- M 10
- KYMR 17
- Target Price
- M $15.72
- KYMR $61.65
- AVG Volume (30 Days)
- M 8.8M
- KYMR 881.2K
- Earning Date
- M 11-25-2025
- KYMR 10-30-2025
- Dividend Yield
- M 4.12%
- KYMR N/A
- EPS Growth
- M 304.55
- KYMR N/A
- EPS
- M 1.77
- KYMR N/A
- Revenue
- M $22,701,000,000.00
- KYMR $44,711,000.00
- Revenue This Year
- M N/A
- KYMR $62.11
- Revenue Next Year
- M N/A
- KYMR N/A
- P/E Ratio
- M $10.04
- KYMR N/A
- Revenue Growth
- M N/A
- KYMR N/A
- 52 Week Low
- M $9.76
- KYMR $19.45
- 52 Week High
- M $18.47
- KYMR $59.00
- Technical
- Relative Strength Index (RSI)
- M 60.50
- KYMR 66.17
- Support Level
- M $17.54
- KYMR $56.02
- Resistance Level
- M $18.47
- KYMR $59.00
- Average True Range (ATR)
- M 0.55
- KYMR 2.23
- MACD
- M -0.13
- KYMR 0.18
- Stochastic Oscillator
- M 56.17
- KYMR 82.03
About M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.